Abstract
Despite the consistent and significant advancements made in the treatment of head and neck cancer (HNSCC), it remains one of the most devastating cancers globally killing approximately 350,000 people every year. Both clinical and basic research revealed that the transcription factor NF-κB, is constitutively expressed in HNSCC and this persistent expression of NF-κB is the root cause of this disease resulting in cancer cell proliferation, survival, invasion, metastases and poor survival of patients. Activation of NF-κB is pragmatic in most of the premalignant dysplastic lesions indicating it as an early episode in malignant transformation of this disease. Therefore, therapies designed to inhibit or block the activity of NF-κB, would result in downregulation of key cellular processes involved in tumor growth and its dissemination to metastatic sites. In addition, substantial evidences have revealed that NF-κB plays an indispensable role in the development of both chemo and radiation resistance in HNSCC which is identified to be a primary cause for the failure of therapies. This shows the potential of targeting NF- κB in developing therapies against this disease. This review summarises the role of NF-κB in the development of HNSCC and the potential of using NF-κB as a target to develop novel highly effective therapies for this disease.
Keywords: NF-κB, IκBα, head and neck cancer, oral squamous cell carcinoma, cytokines, NF-κB inhibitors.
Current Drug Targets
Title:Nuclear Factor Kappa B: A Potential Target to Persecute Head and Neck Cancer
Volume: 18 Issue: 2
Author(s): Javadi Monisha, Nand Kishor Roy, Devivasha Bordoloi, Amit Kumar, Ramesh Golla, Jibon Kotoky, Ganesan Padmavathi and Ajaikumar B. Kunnumakkara
Affiliation:
Keywords: NF-κB, IκBα, head and neck cancer, oral squamous cell carcinoma, cytokines, NF-κB inhibitors.
Abstract: Despite the consistent and significant advancements made in the treatment of head and neck cancer (HNSCC), it remains one of the most devastating cancers globally killing approximately 350,000 people every year. Both clinical and basic research revealed that the transcription factor NF-κB, is constitutively expressed in HNSCC and this persistent expression of NF-κB is the root cause of this disease resulting in cancer cell proliferation, survival, invasion, metastases and poor survival of patients. Activation of NF-κB is pragmatic in most of the premalignant dysplastic lesions indicating it as an early episode in malignant transformation of this disease. Therefore, therapies designed to inhibit or block the activity of NF-κB, would result in downregulation of key cellular processes involved in tumor growth and its dissemination to metastatic sites. In addition, substantial evidences have revealed that NF-κB plays an indispensable role in the development of both chemo and radiation resistance in HNSCC which is identified to be a primary cause for the failure of therapies. This shows the potential of targeting NF- κB in developing therapies against this disease. This review summarises the role of NF-κB in the development of HNSCC and the potential of using NF-κB as a target to develop novel highly effective therapies for this disease.
Export Options
About this article
Cite this article as:
Monisha Javadi, Roy Kishor Nand, Bordoloi Devivasha, Kumar Amit, Golla Ramesh, Kotoky Jibon, Padmavathi Ganesan and Kunnumakkara B. Ajaikumar, Nuclear Factor Kappa B: A Potential Target to Persecute Head and Neck Cancer, Current Drug Targets 2017; 18 (2) . https://dx.doi.org/10.2174/1389450117666160201112330
DOI https://dx.doi.org/10.2174/1389450117666160201112330 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Epigenome-Wide Association Studies (EWAS) in Cancer
Current Genomics Exfoliated Epithelial Cells: A Non-Invasive way to Evaluate the Physiological State of Gastrointestinal Epithelium
Recent Patents on Biomedical Engineering (Discontinued) Oncolytic Virus Therapy - Foreword
Current Cancer Drug Targets Potent Phosphatidylinositol 3-Kinase Inhibitors and Their Biology
Current Drug Discovery Technologies Cancer Vaccines for Hormone/Growth Factor Immune Deprivation:A Feasible Approach for Cancer Treatment
Current Cancer Drug Targets Novel Oral Anticoagulants: Recommendations for Patient Evaluation, Treatment Initiation, Follow-up and Perioperative Management
Cardiovascular & Hematological Disorders-Drug Targets PI-3-Kinase Inhibitors in Colorectal Cancer
Current Cancer Drug Targets Targeting Tumors with Small Molecule Peptides
Current Cancer Drug Targets Recent Advances in the Signal Transduction Targeting of Colorectal Cancer: The Paradigm of Translational Medicine
Current Signal Transduction Therapy The Interplay between Indoleamine 2,3-Dioxygenase 1 (IDO1) and Cyclooxygenase (COX)-2 In Chronic Inflammation and Cancer
Current Medicinal Chemistry Oncogene-Blocking Therapies: New Insights from Conditional Mouse Tumor Models
Current Cancer Drug Targets Docosahexaenoic Acid (DHA) Sensitizes Brain Tumor Cells to Etoposide-Induced Apoptosis
Current Molecular Medicine Editorial
Pharmaceutical Nanotechnology Challenges in the Correct Assessment of a Case of Aggressive Thyroid Carcinoma with Synchronous Breast Cancer: A Case Report and Review of the Literature of Essential Role of Radiopharmaceuticals
Current Radiopharmaceuticals Impact of Drug Metabolism/Pharmacokinetics and their Relevance Upon Taxus-based Drug Development
Current Drug Metabolism Development of Cancer Vaccine Targeting WT1 Product which is Expressed in Various Kinds of Malignant Neoplasms
Medicinal Chemistry Reviews - Online (Discontinued) Epi-Drugs and Epi-miRs: Moving Beyond Current Cancer Therapies
Current Cancer Drug Targets The Mouse In Cancer Research Past, Present, Future
Current Genomics Nonsteroidal Anti-Inflammatory Drugs: Exploiting Bivalent COXIB/ TP Antagonists for the Control of Cardiovascular Risk
Current Medicinal Chemistry Electrochemotherapy: Progress and Prospects
Current Pharmaceutical Design